pirfenidone has been researched along with 2019 Novel Coronavirus Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 14 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acat, M; Oner, S; Turan, MK; Yildiz Gulhan, P | 1 |
| Comes, A; Lerede, M; Richeldi, L; Sgalla, G | 1 |
| Concepción Carrillo, LE; Iturbe Esquivel, B; Mendieta Zeron, H; Meneses Calderón, J | 1 |
| Adamali, HI; Chambers, DC; Chaudhuri, N; Cox, PG; Danoff, SK; Dellaripa, PF; Flaherty, KR; Forrest, IA; Gibbons, MA; Glaspole, I; Goldberg, HJ; Golden, J; Gooptu, B; Hurwitz, S; Kolb, M; Lasky, JA; Lynch, DA; Maurer, R; Perrella, MA; Raghu, G; Rosas, IO; Scholand, MB; Solomon, JJ; Spencer, LG; Spino, C; Troy, L; Vassallo, R; Woodhead, FA | 1 |
| Crooks, JL; Fernández Pérez, ER; Fier, K; Groshong, SD; Humphries, SM; Koelsch, TL; Lynch, DA; Mohning, MP; Solomon, JJ; Swigris, JJ | 1 |
| Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO | 1 |
| Chang, WT; Liu, PY; Ragazzi, E; Wu, SN | 1 |
| Seifirad, S | 1 |
| Ferrara, F; Granata, G; La Porta, R; Pelliccia, C; Vitiello, A | 1 |
| Aguirre-Plans, J; Artigas, L; Barbera, J; Coma, M; de la Haba-Rodriguez, J; Farrés, J; Fernandez-Fuentes, N; Mas, JM; Matos-Filipe, P; Morales, R; Oliva, B; Olvera, A; Valls, R | 1 |
| Li, JW; Tan, K; Wang, GQ; Wu, Z; Yang, W; Zhang, C; Zhao, H | 1 |
| Li, SQ; Zou, H | 1 |
| Hamidi, SH; Kadamboor Veethil, S | 1 |
| Bari, E; Corsico, AG; Ferrarotti, I; Perteghella, S; Richeldi, L; Saracino, L; Torre, ML | 1 |
4 review(s) available for pirfenidone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-related fibrosis: insights into potential drug targets.
Topics: Animals; Antifibrotic Agents; COVID-19; Critical Illness; Humans; Indoles; Pulmonary Fibrosis; Pyridones | 2021 |
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Inflammation; Interleukin-1; Interleukin-6; Pandemics; Pneumonia, Viral; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2020 |
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Indoles; Lung; Patient Discharge; Pulmonary Fibrosis; Pyridones; Severity of Illness Index; Signal Transduction | 2021 |
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; COVID-19 Drug Treatment; Humans; Inflammation; Lung Injury; Pyridones; SARS-CoV-2; Signal Transduction; Transforming Growth Factor beta | 2021 |
3 trial(s) available for pirfenidone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Arthritis, Rheumatoid; COVID-19; Double-Blind Method; Humans; Lung Diseases, Interstitial; Pandemics; Treatment Outcome | 2023 |
Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety.
Topics: Adult; Alveolitis, Extrinsic Allergic; COVID-19; Disease Progression; Double-Blind Method; Humans; Idiopathic Pulmonary Fibrosis; Pandemics; Pyridones; Treatment Outcome; Vital Capacity | 2023 |
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones | 2023 |
7 other study(ies) available for pirfenidone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antifibrotic Agents; Artificial Intelligence; COVID-19; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Retrospective Studies; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2021 |
Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series.
Topics: Adult; Colchicine; COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; SARS-CoV-2 | 2022 |
Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.
Topics: Animals; Betacoronavirus; Cations; Cell Line, Tumor; Cell Membrane; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Ion Channels; Ion Transport; Membrane Potentials; Pandemics; Pneumonia, Viral; Potassium; Pyridones; Rats; SARS-CoV-2; Sodium | 2020 |
Pirfenidone: A novel hypothetical treatment for COVID-19.
Topics: Alveolar Epithelial Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Apoptosis; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Disease Models, Animal; Down-Regulation; Drug Repositioning; Humans; Lipid Peroxidation; Oxidative Stress; Pyridones; Receptors, Virus | 2020 |
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Pharmaceutical; Drug Repositioning; Furin; Humans; Melatonin; Pandemics; Pneumonia, Viral; Pyridones | 2020 |
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
Topics: Acetylcysteine; Convalescence; COVID-19; COVID-19 Drug Treatment; Early Medical Intervention; Glucocorticoids; Humans; Indoles; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2021 |
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
Topics: Biological Factors; COVID-19; COVID-19 Drug Treatment; Humans; Indoles; Lung; Mesenchymal Stem Cells; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2021 |